In this exclusive interview from UROonco24, Dr. Juan Gómez Rivas and Dr. Ursula Vogl discuss advancements in genomic profiling and the use of PARP inhibitors in treating metastatic prostate cancer, with a focus on genomic profiling, patient selection and toxicity management.
